MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

MSX-122

CAS No. : 897657-95-3

MCE 站：MSX-122

产品活性：MSX-122 是一种可口服的 CXCR4 的部分拮抗剂，抑制 CXCR4/CXCL12 相互作用，IC₅₀ 值约为 10 nM。MSX-122 具有抗炎和抗转移的活性。

研究领域：GPCR/G Protein  |  Immunology/Inflammation

作用靶点：CXCR

In Vitro: MSX-122 is a partial antagonist of CXCR4, inhibiting CXCR4/CXCL12 actions, with an IC₅₀ of ?10 nM. MSX-122 shows no inhibition on cAMP reduction mediated by their corresponding ligands CCR3/CCL5 and CCR5/CCL5. MSX-122 (100 nM) potently blocks invasion of 78% MDA-MB-231 cells. However, MSX-122 does not suppress T-tropic HIV infection and is inactive in calcium flux assay.

In Vivo: MSX-122 (10 mg/kg, i.p.) blocks inflammation induced by carrageenan and lung fibrosis induced by bleomycin in mice. MSX-122 (4 mg/kg, i.p., daily) blocks metastasis in an experimental animal model of breast cancer metastasis. Furthermore, MSX-122 (10 mg/kg i.p., daily) significantly decreases the numbers of hepatic micrometastases.

相关产品：Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Immunology/Inflammation Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Small Molecule Immuno-Oncology Compound Library  |  Endocrinology Compound Library  |  Orally Active Compound Library  |  Anti-Breast Cancer Compound Library  |  SB225002  |  Reparixin  |  Motixafortide  |  TAK-779  |  IT1t dihydrochloride  |  NBI-74330  |  Baohuoside I  |  AMD 3465 hexahydrobromide  |  ATI-2341 TFA  |  CXCR2-IN-1  |  FC131 TFA  |  ALX 40-4C Trifluoroacetate  |  SRT3109  |  PS372424 hydrochloride  |  SRT3190  |  VUF11207 fumarate  |  UNBS5162  |  CXCR7 modulator 1  |  Nicotinamide N-oxide  |  SB-265610  |  Antileukinate  |  Corydalmine  |  CTCE-9908  |  MSX-127

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。